Vaptan Therapy

Vaptan Therapy is a pharmacological treatment modality that belongs to the class of targeted antidiuretic hormone antagonists, specifically characterized by its selective inhibition of vasopressin V2 receptors in the renal collecting ducts to promote aquaresis in patients with hyponatremia associated with ascites.

16

Publications

619

Citations

56

Authors

41

Institutions

Publications per year

2017–2026

5

Variants

Vasopressin Receptor Antagonist Therapy

Authors

56

  1. GS
    Gökçe Süral

    Ankara University, Türkiye

    1 publications · 12 citations

    1

    h-index

  2. SA
    Suruchi Aditya

    Maulana Azad Institute of Dental Sciences, India

    1 publications · 47 citations

    1

    h-index

  3. PG
    Pere Ginès

    Universitat de Barcelona, Spain

    1 publications · 43 citations

    1

    h-index

  4. SG
    Sheldon Greenberg

    Maimonides Medical Center, United States

    1 publications · 41 citations

    1

    h-index

  5. SK
    Shree K. Sharma

    Maimonides Medical Center, United States

    1 publications · 41 citations

    1

    h-index

1–5 of 56

Venues

  1. Core evidence

    1 publications · 27 citations

    1

    h-index

  2. Clinical Journal of the American Society of Nephrology

    CJASN · 1 publications · 154 citations

    1

    h-index

  3. 1

    h-index

  4. Alimentary Pharmacology & Therapeutics

    1 publications · 43 citations

    1

    h-index

  5. 1

    h-index

1–5